How long does Lorlatinib/Lorlatinib (Borina) treatment extend your life on average?

Lorlatinib/Lorlatinib (Lorlatinib) is a targeted therapy drug mainly used to treat patients with ALK-positive non-small cell lung cancer (NSCLC), especially those who have developed resistance to other ALK inhibitors. In the treatment of advanced lung cancer, prolonging patient survival is one of the main goals of targeted drugs. Lorlatinib has shown significant efficacy in clinical trials, especially in drug-resistant patients.

Although the specific survival prolongation time of different patients may vary depending on factors such as disease, medication regimen, and physical condition, existing research data shows that lorlatinib has a certain effect on prolonging the progression-free survival (PFS) and overall survival (OS) of patients. According to some clinical data, lorlatinib can effectively inhibit tumor progression, especially in patients who are resistant to previous treatment drugs. The use of lorlatinib helps patients prolong progression-free survival, which means that during treatment, the growth of tumors is effectively controlled and the patient's quality of life is maintained.

Specifically, when treating patients with drug-resistantALK-positive non-small cell lung cancer, the efficacy of lorlatinib was shown to extend survival from several months to one year. Some patients can even achieve a longer survival after receiving treatment, which makes lorlatinib a very important treatment drug for patients with strong drug resistance. Although lorlatinib can effectively prolong patient survival, the specific therapeutic effect varies between individuals.

In summary, lorlatinib showed positive clinical effects in extending survival in patients with advanced non-small cell lung cancer. For patients who have developed resistance to other ALK inhibitors, lorlatinib provides an effective treatment option that can significantly extend patients' lives and improve their quality of life.

References：https://www.lorbrena.com/